Characterization of non-monotonic relationships between tumor mutational burden and clinical outcomes
Abstract
Potential clinical biomarkers are often assessed with Cox regressions or their ability to differentiate two groups of patients based on a single cutoff. However, both of these approaches assume a monotonic relationship between the potential biomarker and survival. Tumor mutational burden (TMB) is currently being studied as a predictive biomarker for immunotherapy, and a single cutoff is often used to divide patients. In this study we introduce a two-cutoff approach that allows splitting of patients when a non-monotonic relationship is present, and explore the use of neural networks to model more complex relationships of TMB to outcome data. Using real-world data we find that while in most cases the true relationship between TMB and survival appears monotonic, that is not always the case and researchers should be made aware of this possibility. SignificanceWhen a non-monotonic relationship to survival is present it is not possible to divide patients by a single value of a predictor. Neural networks allow for complex transformations and can be used to correctly split patients when a non-monotonic relationship is present.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 1
- FWCI
- 0.17
- Field percentile
- 49th percentile
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Burden of tumor mutations, neoepitopes, and other variants are dubious predictors of cancer immunotherapy response and overall survival
M. A. Wood, B. R. Weeder, … R. F. Thompson·bioRxiv·Jan 28, 2020
- Revisiting Tumor Mutational Burden Cutoff: Multi-Study Replicability in Immunotherapy
Iman Jaljuli, Karissa A. Whiting, … Li‐Xuan Qin·bioRxiv·Jan 2, 2025
- Non-B DNA-Informed Mutation Burden as a Marker of Treatment Response and Outcome in Cancer
Q. Xu, J. Kowalski·bioRxiv·Jan 4, 2024
- ecTMB: a robust method to estimate and classify tumor mutational burden
Lijing Yao, Yao Fu, … Hugo Y. K. Lam·Scientific ReportsPeer-reviewed·Mar 18, 2020
- AlphaMissense pathogenicity scores predict response to immunotherapy and enhances the predictive capability of tumor mutation burden
David Adeleke, Adewale Oluwaseun Fadaka, … Rick J. Jansen·Translational OncologyPeer-reviewed·Feb 3, 2026
- Is tumor mutational burden predictive of response to immunotherapy?
Carino Gurjao, Dina I. Tsukrov, … Leonid A. Mirny·bioRxiv·Sep 3, 2020